Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of GDC-4198 alone or with giredestrant versus abemaciclib + giredestrant in ER-positive, HER2-negative advanced breast cancer after CDK4/6 inhibitor progression
CTR20261043Phase 2Active
- Sponsor
- Genentech
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GDC-4198 in breast cancer, sponsored by Genentech. Started Apr 2026; status: active.
02
Drugs
GDC-4198
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20261043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261043.